Raquel Mata Serna

Consultant in Hematology and Hemotherapy. Flow Cytometry Department and Outpatient Clinics
Specialty:
Hematology and hemotherapy
Serving specialties:
  • Hematología y Hemoterapia
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
General Information
Experience

2007–Present: Consultant in Hematology. Flow Cytometry Laboratory and Outpatient Clinics. Fundación Jiménez Díaz. Madrid.

2005–2007: Consultant in Hematology/ haemostasis Laboratory. Fundación Jiménez Díaz-Unilabs. Madrid.

2005: Consultant in Hematology. Haemostasis Laboratory. Fundación Jiménez Díaz.Madrid.

2004-2005: Responsible physician in Blood donation unit. Red Cross (Transfusion centre). Madrid.

Degree

Bachelor of Medicine and Surgery, Autonomous University of Madrid (1999)

Specialist in Hematology and Hemotherapy (2000–2004)

Techniques

Hematologic flow cytometry studies (screening for B and T CLPD, MM and myeloid disorders (MPN, MDS/acute leukemias...), MRD monitoring in MM, acute leukemias, and CLPD, PNH/spherocytosis screening, CD34+ cell count, glycoprotein studies, platelet activation and secretion, fetal hemoglobin analysis…

Research and teaching

A non-interventional observational post authorisation safety study of subjects treated with lenalidomide". Celgene. 2008-2017. PI.

MANIFEST-2: A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients. Constellation Pharmaceuticals (2021-2023). PI.

A randomized Open-label, Phase 3 study to evaluate Imetelstat versus Best Available Therapy (BAT) in patients with Intermediate-2 or High-risk Myelofibrosis (MF) refractory to Janus Kinase (JAK)-inhibitor. Geron Corporation (2021-actualidad).PI

A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib. Incyte Corporation (2021-2023). PI.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis. Incyte Corporation (2021-2023). PI.

Teaching collaborator Universidad Autónoma de Madrid (UAM)

Publications

JAK-2 as a molecular marker in myeloproliferative diseases. Cardiovasc Hematol Agents Med Chem. 2007; 5(3):198-203.

Antiphospholipid syndrome after non-myeloablative hematopoietic cell transplantation. Trombosis Research 2008; 122(2): 283-284.

Immunophenotype in chronic myelomonocytic leukaemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?. Transl Res 2008; 151 (5):240-245.

Vascular risk factors in patients with ischaemic stroke. Distribution according to age, sex and stroke subtype.Rev Neurol. 2008; 46(10):593-59.

Association between venous thrombosis and dyslipidemia.Med Clin(Barc)2014;143:1-5.

ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report. Medicina (Kaunas) 2022; 58(4):52

Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. 2023 Feb 102 (2):447-456.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Blood Cancer J. 2025 Apr 17;15(1):67.

Spontaneous Remission of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. Medicina. doi: 10.3390/medicina60050807.

Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage. Annals of Hematology. doi: 10.1007/s00277-024-05647-6.

Flow Cytometry analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome eJHaem. In press. doi:10.1002/jha2.7005

Hemorrhagic diathesis. Cliniguía. Update of diagnosis and therapeutic approach. Ed. Eviscience C.B. 2007, 2008 y 2009.

Thrombosis. Cliniguía. Update of diagnosis and therapeutic approach. Ed. Eviscience C.B. 2007, 2008 y 2009

Communications and Presentations

Talk. Thrombosis and cancer. III Congress of AMHH. Madrid. 2008

Talk. Thrombotic risk. I comprehensive care forum for hip fractures in the elderly. Madrid .2009

Basic techniques in Hematology for laboratory technician specialist. AMHH. Madrid .2009

Talk. Day-to-day in the hemostasis laboratory: automation and automated management models. LI National Congress of AEHH. Barcelona .2009

Talk. Pregnancy and thrombosis. V Congress of AMHH. Madrid.2010

Talk. Chronic Myeloproliferative Neoplasms and pregnancy. II Forum Dexeus "Women and thrombosis". Barcelona. 2024

Talk. Chronic Myeloproliferative neoplasms. 18 Congress of GEPAC. Madrid. 2023.

Talk. Chronic Myeloproliferative neoplasms. 19 Congreso GEPAC. Madrid. 2024.

Talk: "Chronic myeloid leukemia... with a twist". Clinical-cytological cases at the interannual meeting of the Spanish Hematologic Cytology Group. 2017. Spain